Medical Services Expenditures by Disease: Neoplasms Price Index, Blended Account Basis (NPSMSMPIBLEND) | FRED | St. Louis Fed
- Rows
- 22
- Columns
- 2
- Data range
- 2000-01-01 to 2021-01-01
Graph and download economic data for Medical Services Expenditures by Disease: Neoplasms Price Index, Blended Account Basis (NPSMSMPIBLEND) from 2000 to 2021 about neoplasms, disease, healthcare, medical, health, expenditures, services, price index, indexes, price, and USA.
AI analysis
Dataset Analysis: Medical Services Expenditures by Disease — Neoplasms Price Index
1. Dataset Representation and Value
This series (NPSMSMPIBLEND) tracks a price index specifically for medical services expenditures related to neoplasms (cancers and tumors), using a "blended account basis" methodology. Sourced from FRED (Federal Reserve Bank of St. Louis) via their public API (fredgraph.csv endpoint), this is a well-curated macroeconomic/health economics series. FRED's reputation as an aggregator of authoritative government and institutional data (this series likely originates from BEA's Health Care Satellite Account) lends credibility to the data. With annual observations spanning 2000–2021, this dataset is valuable for long-run trend analysis of cancer treatment cost inflation, though its low frequency (annual, 22 points) limits its use for short-term or high-frequency correlation studies. It's best suited for longitudinal studies examining how neoplasm treatment pricing has evolved relative to broader healthcare inflation, policy changes (e.g., ACA implementation in 2010), or disease-specific spending patterns.
2. Data Quality Observations
The dataset shows excellent completeness: zero null cells across both columns and zero missing observations (22 rows with 22 distinct values in each column, indicating no duplicate dates or repeated index values). This suggests a clean, audit-ready series suitable for direct use without imputation. The duplicate-row check is flagged as pending recomputation ("Phase D"), so that specific metric isn't yet confirmed — worth revisiting before final validation. Given FRED's data curation standards, I'd expect duplicates to be absent, but this should be verified programmatically before merging with other sources. No type mismatches are reported, and both columns (Date and Decimal) have appropriate, unambiguous types.
3. Key Column Distributions
The core metric, NPSMSMPIBLEND, ranges from a minimum of 62.54 to a maximum of 123.68 — nearly a doubling over the observation period, consistent with substantial cumulative price inflation in cancer treatment costs. The mean (98.33) sits close to the median (101.7), but the negative skew (-0.671) indicates a longer left tail — likely reflecting the lower index values clustered in the early 2000s before the index approached and exceeded the baseline (100) in later years. The interquartile range (Q1=90.43, Q3=111.41) spans about 21 points, suggesting steady, non-explosive growth rather than sharp volatility. The relatively high standard deviation (σ=16.47) relative to the range confirms a strong, consistent multi-year upward trend typical of cumulative price indices rather than a mean-reverting series.
4. Recommended Join Keys
- observationdate is the only viable and appropriate join key. As a clean, fully-populated, annual date field (2000-01-01 to 2021-01-01) with 22 distinct values, it aligns naturally with other annual FRED series or government health/economic datasets. - Analysts should note the annual granularity — joining with monthly or quarterly datasets will require aggregation (e.g., averaging or year-end snapshots) to prevent misalignment.
5. Suggested Pairings for Correlation Analysis
Strong candidates include: - Other FRED disease-specific price indices (e.g., circulatory diseases, musculoskeletal, mental disorders) under the same "Blended Account Basis" family, enabling cross-disease cost comparison. - CPI Medical Care Services (CPIMEDSL) or PCE Healthcare deflators, to benchmark neoplasm-specific inflation against broader medical inflation. - National Health Expenditure (NHE) data from CMS, particularly cancer-specific spending, to correlate price growth with utilization/volume changes. - Cancer incidence/mortality rates (e.g., from SEER or CDC WONDER) to explore whether price growth correlates with disease prevalence or treatment innovation (e.g., new oncology drugs). - Pharmaceutical price indices (e.g., PPI for oncology drugs), since neoplasm treatment costs are heavily influenced by specialty drug pricing trends.
Columns
- observation_date (date)
- NPSMSMPIBLEND (decimal)